| The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes SZ Ali, PA VanderLaan | 1214* | 2003 |
| Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators PA VanderLaan, CA Reardon, GS Getz Arteriosclerosis, thrombosis, and vascular biology 24 (1), 12-22, 2004 | 844 | 2004 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 612 | 2015 |
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ... Lung cancer 88 (1), 108-111, 2015 | 495 | 2015 |
| The 2023 Bethesda System for Reporting Thyroid Cytopathology S Ali, Z Baloch, B Cochand-Priollet, F Schmitt, V Philippe, P VanderLaan Thyroid 33 (9), 1039-1044, 2023 | 264 | 2023 |
| Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? PA VanderLaan, E Marqusee, JF Krane American Journal of Clinical Pathology 135 (5), 770-775, 2011 | 259 | 2011 |
| Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy R Sethi, E Kozin, A Remenschneider, J Meier, P VanderLaan, W Faquin, ... The Laryngoscope 124 (1), 188-195, 2014 | 183 | 2014 |
| Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes PA VanderLaan, D Rangachari, SM Mockus, V Spotlow, HV Reddi, ... Lung cancer 106, 17-21, 2017 | 181 | 2017 |
| Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer PA VanderLaan, N Yamaguchi, E Folch, DH Boucher, MS Kent, ... Lung cancer 84 (1), 39-44, 2014 | 168 | 2014 |
| Thematic review series: The Immune System and Atherogenesis. The unusual suspects: an overview ofthe minor leukocyte populations in atherosclerosis PA VanderLaan, CA Reardon Journal of lipid research 46 (5), 829-838, 2005 | 161 | 2005 |
| Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1≥ 50% expression in lung adenocarcinoma D Rangachari, PA VanderLaan, M Shea, X Le, MS Huberman, ... Journal of thoracic oncology 12 (5), 878-883, 2017 | 148 | 2017 |
| The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio: a proposed performance measure for reporting in The Bethesda System for … JF Krane, PA VanderLaan, WC Faquin, AA Renshaw Cancer Cytopathology 120 (2), 111-116, 2012 | 148 | 2012 |
| Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance PA VanderLaan, E Marqusee, JF Krane American journal of clinical pathology 136 (4), 572-577, 2011 | 124 | 2011 |
| Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: guideline from the college of American pathologists in collaboration with the … S Roy-Chowdhuri, S Dacic, M Ghofrani, PB Illei, LJ Layfield, C Lee, ... Archives of pathology & laboratory medicine 144 (8), 933-958, 2020 | 118 | 2020 |
| Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA): An overview and update for the cytopathologist PA VanderLaan, HH Wang, A Majid, E Folch Cancer cytopathology 122 (8), 561-576, 2014 | 116 | 2014 |
| Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni, SJ Subegdjo, CA Lydon, ... Journal of Thoracic Oncology 13 (7), 1037-1042, 2018 | 95 | 2018 |
| Fine‐needle aspiration and core needle biopsy: an update on 2 common minimally invasive tissue sampling modalities PA VanderLaan Cancer cytopathology 124 (12), 862-870, 2016 | 95 | 2016 |
| Lung adenocarcinoma manifesting as pure ground-glass nodules: correlating CT size, volume, density, and roundness with histopathologic invasion and size BH Heidinger, KR Anderson, U Nemec, DB Costa, SP Gangadharan, ... Journal of Thoracic Oncology 12 (8), 1288-1298, 2017 | 93 | 2017 |
| Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation SE Jorge, S Schulman, JA Freed, PA VanderLaan, D Rangachari, ... Lung cancer 90 (3), 369-374, 2015 | 91 | 2015 |
| Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis PA VanderLaan, CA Reardon, Y Sagiv, L Blachowicz, J Lukens, ... The American journal of pathology 170 (3), 1100-1107, 2007 | 87 | 2007 |
Daniel Botelho CostaProfessor of Medicine | Harvard Medical School | Beth Israel Deaconess Medical CenterDirección de correo verificada de bidmc.harvard.edu
